A Study of BL-B01D1 in Patients With Recurrent Glioblastoma

Clinical trial NCT06598787 · RECRUITING

Trial details

NCT number: NCT06598787
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Glioblastoma

Start date: 2024-10-17
Primary completion: 2026-10-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.